ARCHIVES

FDA Approval Of Two Generic Versions Of Taxol Likely To End BMS Exclusivity.

This article is from The Cancer Letter archive.

Vol. 26 No. 35 | September 29, 2000

Download PDF Visit The Full Archive

Related Articles

IDMC Recommends Halting Phase III Trial Of Onartuzumab in MET-Positive NSCLC

March 28, 2014

Bush Appoints Kripke To President’s Cancer Panel

March 21, 2003

In Brief: FDA Advisors Ask Cetus To Refine IL-2 Application; NIH Reauthorization Introduced

August 3, 1990

MGI Pharma, MethylGene Begin Phase II Trial Of MG98.

September 28, 2001

Loss Of Core Grants Imperials Status Of Three Comprehensive Cancer Centers

July 14, 1989

NCAB Subcommittee drafting Report Bioassay-Human Risk Relationship

February 16, 1979